Marker Therapeutics (MRKR) Net Cash Flow (2010 - 2026)
Marker Therapeutics (MRKR) posted quarterly Net Cash Flow of -$1.4 million for Q1 2026, up 74.47% year-over-year from -$804852.9 in Q1 2025, and up 26.1% quarter-over-quarter from -$1.9 million in Q4 2025.
Marker Therapeutics (MRKR) Net Cash Flow (2010 - 2026) Analysis & Trends
Marker Therapeutics (MRKR) has reported Net Cash Flow for 17 consecutive years, with -$1.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow rose 74.47% year-over-year to -$1.4 million; the TTM figure through Mar 2026 stood at $1.9 million (down 17.91% YoY), while the FY2025 annual figure was -$2.1 million, down 152.67% from the prior year.
- Net Cash Flow rose to -$1.4 million in Q1 2026 per MRKR's latest filing, from -$1.9 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $17.5 million in Q2 2023 and bottomed at -$14.7 million in Q1 2022.
- Historically, Net Cash Flow has averaged -$958867.9 across 5 years, with a median of -$3.0 million in 2022.
- Annual changes were most pronounced in 2022 — Net Cash Flow sank 134.01% — and 2023, when it soared 683.73%.
- Marker Therapeutics' Net Cash Flow stood at -$4.1 million in 2022, then soared by 191.31% to $3.7 million in 2023, then soared by 172.79% to $10.2 million in 2024, then slumped by 118.64% to -$1.9 million in 2025, then gained by 26.1% to -$1.4 million in 2026.
- Business Quant data shows MRKR's Net Cash Flow at -$1.4 million in Q1 2026, -$1.9 million in Q4 2025, and $7.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.69 Bn | 131.84 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.54 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 65.27 Bn | 60.09 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.41 Bn | 54.27 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.07 Bn | 9.68 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.28 Bn | 26.44 Bn | - | 225.59 Mn |
| 10 | Marker Therapeutics | 26.94 Mn | 15.01 Mn | - | -3.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.40 Mn |
| Mar 31, 2026 | -1.40 Mn |
| Dec 31, 2025 | -1.90 Mn |
| Dec 31, 2025 | -1.90 Mn |
| Sep 30, 2025 | 7.13 Mn |
| Sep 30, 2025 | 7.13 Mn |
| Jun 30, 2025 | -1.88 Mn |
| Jun 30, 2025 | -1.88 Mn |
| Mar 31, 2025 | -5.50 Mn |
| Mar 31, 2025 | -5.50 Mn |
| Dec 31, 2024 | 10.19 Mn |
| Dec 31, 2024 | 10.19 Mn |
| Sep 30, 2024 | 1.20 Mn |
| Sep 30, 2024 | 1.20 Mn |
| Jun 30, 2024 | -3.52 Mn |
| Jun 30, 2024 | -3.52 Mn |
| Mar 31, 2024 | -3.79 Mn |
| Mar 31, 2024 | -3.79 Mn |
| Dec 31, 2023 | 3.74 Mn |
| Dec 31, 2023 | 3.74 Mn |